R. Dellamano

Multi-indication Pricing: Pros, Cons and Applicability to the UK

A. Towse, J. Mestre-Ferrandiz, M. Pistollato, 2015 .

[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective

F. Spada, O. Leeuwenkamp, R. Laudicella, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective

F. Spada, O. Leeuwenkamp, R. Laudicella, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective

R. Dellamano, L. Dellamano, J. Mycka, 2022, Value in Health.

Cost-effectiveness comparison of single and multiple-dose antibiotic treatment of lower uncomplicated urinary tract infections.

S. Capri, R. Dellamano, G. D. Del Bono, 1992, Journal of chemotherapy.

Orphan Drugs Assessment in Germany: A Comparison with Other International HTA Agencies.

R. Dellamano, L. Dellamano, J. Mycka, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness in the hospital use of antibiotics: introductory considerations.

S. Capri, R. Dellamano, 1993, Journal of chemotherapy.